Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $40.5 million.

  • Akebia Therapeutics' Other Non-Current Assets rose 4911.92% to $40.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.5 million, marking a year-over-year increase of 4911.92%. This contributed to the annual value of $37.4 million for FY2024, which is 20086.94% up from last year.
  • According to the latest figures from Q3 2025, Akebia Therapeutics' Other Non-Current Assets is $40.5 million, which was up 4911.92% from $44.2 million recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Other Non-Current Assets registered a high of $69.6 million during Q3 2021, and its lowest value of $3.3 million during Q2 2023.
  • Over the past 5 years, Akebia Therapeutics' median Other Non-Current Assets value was $35.0 million (recorded in 2022), while the average stood at $30.3 million.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first plummeted by 9042.14% in 2023, then skyrocketed by 60258.93% in 2024.
  • Over the past 5 years, Akebia Therapeutics' Other Non-Current Assets (Quarter) stood at $50.4 million in 2021, then plummeted by 89.35% to $5.4 million in 2022, then soared by 131.25% to $12.4 million in 2023, then surged by 200.87% to $37.4 million in 2024, then increased by 8.25% to $40.5 million in 2025.
  • Its last three reported values are $40.5 million in Q3 2025, $44.2 million for Q2 2025, and $38.3 million during Q1 2025.